Back to Search Start Over

Metabolomics enables precision medicine: “A White Paper, Community Perspective”

Authors :
Beger, Richard D.
Dunn, Warwick B.
Schmidt, Michael A.
Cross, Steven S.
Kirwan, Jennifer A.
Cascante, Marta S.
Brennan, Lorraine
Wishart, David S.
Orešič, Matej
Hankemeier, Thomas
Broadhurst, David
Lane, Andrew N.
Suhre, Karsten
Kastenmüller, Gabi
Sumner, Susan J.
Thiele, Ines
Fiehn, Oliver E.
Kaddurah- Daouk, Rima
Beger, Richard D.
Dunn, Warwick B.
Schmidt, Michael A.
Cross, Steven S.
Kirwan, Jennifer A.
Cascante, Marta S.
Brennan, Lorraine
Wishart, David S.
Orešič, Matej
Hankemeier, Thomas
Broadhurst, David
Lane, Andrew N.
Suhre, Karsten
Kastenmüller, Gabi
Sumner, Susan J.
Thiele, Ines
Fiehn, Oliver E.
Kaddurah- Daouk, Rima
Source :
Research outputs 2014 to 2021
Publication Year :
2016

Abstract

Introduction:Background to metabolomics: Metabolomics is the comprehensive study of the metabolome, the repertoire of biochemicals (or small molecules) present in cells, tissues, and body fluids. The study of metabolism at the global or “-omics” level is a rapidly growing field that has the potential to have a profound impact upon medical practice. At the center of metabolomics, is the concept that a person’s metabolic state provides a close representation of that individual’s overall health status. This metabolic state reflects what has been encoded by the genome, and modified by diet, environmental factors, and the gut microbiome. The metabolic profile provides a quantifiable readout of biochemical state from normal physiology to diverse pathophysiologies in a manner that is often not obvious from gene expression analyses. Today, clinicians capture only a very small part of the information contained in the metabolome, as they routinely measure only a narrow set of blood chemistry analytes to assess health and disease states. Examples include measuring glucose to monitor diabetes, measuring cholesterol and high density lipoprotein/low density lipoprotein ratio to assess cardiovascular health, BUN and creatinine for renal disorders, and measuring a panel of metabolites to diagnose potential inborn errors of metabolism in neonates. Objectives of White Paper—expected treatment outcomes and metabolomics enabling tool for precision medicine: We anticipate that the narrow range of chemical analyses in current use by the medical community today will be replaced in the future by analyses that reveal a far more comprehensive metabolic signature. This signature is expected to describe global biochemical aberrations that reflect patterns of variance in states of wellness, more accurately describe specific diseases and their progression, and greatly aid in differential diagnosis. Such future metabolic signatures will: (1) provide predictive, prognostic, diagnostic, and surroga

Details

Database :
OAIster
Journal :
Research outputs 2014 to 2021
Notes :
application/pdf, Research outputs 2014 to 2021
Publication Type :
Electronic Resource
Accession number :
edsoai.on1366577576
Document Type :
Electronic Resource